Skip to main content
Log in

Cutaneous adverse effects during ipilimumab treatment for metastatic melanoma: a prospective study

  • Clinical report
  • Published:
European Journal of Dermatology Aims and scope

Abstract

Background

Ipilimumab is an immunomodulatory antibody directed against cytotoxicT-lymphocyte-associated antigen 4 (CTLA-4), which is administered to patients with advanced melanoma, with a proven positive effect on overall survival. The cutaneous adverse effects (AEs) of ipilimumab are relatively frequent, although described as usually mild and rarely life threatening.

Objectives

To describe a three-year experience of a single institute in detecting and managing cutaneous AEs.

Materials & Methods

A cohort of patients (n = 41) treated with ipilimumab (3 mg/kg/three weeks) for metastatic melanoma, from 2013 to 2016,was investigated for adverse cutaneous events.

Results

On dermatological evaluation, 34.1% of the patients in our series developed cutaneous AEs: rash (7.3%; n = 3), folliculitis (7.3%; n = 3), mucositis (2.4%; n = 1), rosacea (2.4%; n = 1), eczema (2.4%; n = 1), acneiform eruption (2.4%; n = 1), syringometaplasia mucinosa (2.4%; n = 1), Stevens-Johnson syndrome (2.4%; n = 1), and vitiligo (4.9%; n = 2). These were all Grade 1 and 2 AEs, except for the case of Stevens-Johnson syndrome (Grade 4). On a patient-reported scale, 4.9% (n = 2) and 9.8% (n = 4) of the patients complained of severe xerosis and pruritus, respectively.

Conclusion

Ipilimumab was relatively well tolerated in our series, mainly causing mild cutaneous AEs, which, in our experience, responded satisfactorily to conventional therapies. Only in one case was the treatment discontinued, due to Grade 4 side effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Naidoo J, Page DB, Li BT, et al. Toxicities of the anti-PD-1 andanti-PD-L1 immune checkpoint antibodies. Ann Oncol 2015; 26: 2375.

    CAS  PubMed  Google Scholar 

  2. Champiat S, Lambotte O, Barreau E, et al. Management of immunecheckpoint blockade dysimmune toxicities: a collaborative positionpaper. Ann Oncol 2016; 27: 559.

    Article  CAS  PubMed  Google Scholar 

  3. Chen AP, Setser A, Anadkat MJ, et al. Grading dermatologicadverse events of cancer treatments: The Common Terminology Criteriafor Adverse Events Version 4.0. J Am Acad Dermatol 2012; 67: 1025–39.

    Article  PubMed  Google Scholar 

  4. Williamson A, Hoggart B. Pain: a review of three commonly usedpain rating scales. J Clin Nurs 2005; 14: 798–804.

    Article  PubMed  Google Scholar 

  5. Hofmann L, Forschner A, Loquai C, et al. Cutaneous, gastrointestinal,hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. EurJ Cancer 2016; 60: 190e209.

    Article  CAS  Google Scholar 

  6. Weber JS, Kähler KC, Hauschild A. Management of immune-relatedadverse events and kinetics of response with ipilimumab. J Clin Oncol 2012; 30: 2691.

    Article  CAS  PubMed  Google Scholar 

  7. Lacouture ME, Wolchok JD, Yosipovitch G, et al. Ipilimumab inpatients with cancer and the management of dermatologic adverseevents. J Am Acad Dermatol 2014; 71: 161.

    Article  CAS  PubMed  Google Scholar 

  8. Minkis K, Garden BC, Wu S, Pulitzer MP, Lacouture ME. The riskof rash associated with ipilimumab in patients with cancer: a systematicreview of the literature and meta-analysis. J Am Acad Dermatol 2013; 69: e121–8.

    Article  Google Scholar 

  9. Spain L, Diem S, Larkin J. Management of toxicities of immunecheckpoint inhibitors. Cancer Treat Rev 2016; 44: 51–60.

    Article  CAS  PubMed  Google Scholar 

  10. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combinednivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373: 23–34.

    Article  PubMed  Google Scholar 

  11. Ludlow SP, Kay N. Delayed dermatologic hypersensitivity reactionsecondary to ipilimumab. J Immunother 2015; 38: 165–6.

    Article  PubMed  Google Scholar 

  12. Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumabin advanced melanoma. N Engl J Med 2015; 372: 2521–32.

    Article  CAS  PubMed  Google Scholar 

  13. Robert C, Long GV, Brady B, et al. Nivolumab in previouslyuntreated melanoma without BRAF mutation. N Engl J Med 2015; 372: 320–30.

    Article  CAS  PubMed  Google Scholar 

  14. Weber JS, D’Angelo SP, Minor D, et al. Nivolumab versuschemotherapy in patients with advanced melanoma who progressedafter anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled,open-label, phase 3 trial. Lancet Oncol 2015; 16: 375–84.

    Article  CAS  PubMed  Google Scholar 

  15. Hua C, Boussemart L, Mateus C, et al. Association of vitiligowith tumor response in patients with metastatic melanoma treated withpembrolizumab. JAMA Dermatol 2016; 152: 45–51.

    Article  PubMed  Google Scholar 

  16. Klein O, Ebert LM, Nicholaou T, et al. Melan-A-specific cytotoxic Tcells are associated with tumor regression and autoimmunity followingtreatment with anti-CTLA-4. Clin Cancer Res 2009; 15: 2507–13.

    Article  CAS  PubMed  Google Scholar 

  17. Pintova S, Sidhu H, Friedlander PA, Holcombe RF. Sweet’s syndromein a patient with metastatic melanoma after ipilimumab therapy. Melanoma Res 2013; 23: 498.

    Article  PubMed  Google Scholar 

  18. Abdel-Rahman O, ElHalawani H, Fouad M. Risk of cutaneoustoxicities in patients with solid tumors treated with immune checkpointinhibitors: a meta-analysis. Future Oncol 2015; 11: 2471–84.

    Article  CAS  PubMed  Google Scholar 

  19. Dick J, Lang N, Slynko A, et al. Use of LDH and autoimmune sideeffects to predict response to ipilimumab treatment. Immunotherapy 2016; 8: 1033–44.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Giulia Maria Ravaioli.

Additional information

To cite this article: Dika E, Ravaioli GM, Fanti PA, Piraccini BM, Lambertini M, Chessa MA, Baraldi C, Ribero S, Andrea A, Melotti B, Patrizi A. Cutaneous adverse effects during ipilimumab treatment for metastatic melanoma: a prospective study. Eur J Dermatol 2017; 27(3): 266-70 doi:10.1684/ejd.2017.3023

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dika, E., Ravaioli, G.M., Fanti, P.A. et al. Cutaneous adverse effects during ipilimumab treatment for metastatic melanoma: a prospective study. Eur J Dermatol 27, 266–270 (2017). https://doi.org/10.1684/ejd.2017.3023

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1684/ejd.2017.3023

Key words

Navigation